1 Answers
Cabergoline is to be administered by the oral route. It should be preferably taken with meals.
The recommended dosage of Cabergoline tablets for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient's serum prolactin level. Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient's response to each dosage level. If the patient does not respond adequately and no additional benefit is observed with higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered. After a normal serum prolactin level has been maintained for 6 months, Cabergoline may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when treatment with Cabergoline should be reinstituted.
Inhibition of physiological lactation: Cabergoline should be administered during the first day after delivery. The recommended therapeutic dose is 1mg (two 0.5mg tablets) as a single dose.
To stop lactation once have started to breastfeed: 0.25 mg (one half of Cabergoline 0.5 mg tablet) every 12 hours for two days.
Treatment of hyperprolactinaemic disorders: The recommended initial dosage of Cabergoline is 0.5mg per week given in one or two (½ of a 0.5mg tablet) doses (e.g. on Monday and Thursday) per week. The weekly dose should be increased gradually preferably by adding 0.5mg per week at monthly intervals. The therapeutic dosage is usually 1mg per week and ranges from 0.25 to 2mg per week. Doses of Cabergoline up to 4.5mg per week have been used in hyperprolactinaemic patients until the optimal therapeutic response is achieved.
Severe hepatic insufficiency: Lower doses should be considered in patients with severe hepatic insufficiency.
Children: The safety and efficacy of Cabergoline has not been established in subjects less than 16 years of age.
Elderly: Data for use of Cabergoline in elderly is very limited. Available data do not indicate a special risk.
আরগোলিন ট্যাবলেট সম্পর্কে বিস্তারিত জেনে নিন এই লিঙ্ক থেকে আরগোলিন